Loading stock data…
CCRN
$10.23+0.11 (+1.09%)
Market ClosedLast close May 1
Cross Country Healthcare, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cross Country Healthcare, Inc. in the Healthcare sector is trading at $10.23. The stock is currently 32% below its 52-week high of $14.99, remaining 5.7% below its 200-day moving average. Technical signals show neutral RSI of 64 and bullish MACD crossover, explaining why CCRN maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 64) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.23
Potential Upside
5%
Whystock Fair Value$10.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$11.67+14.0%
Range$10.00 – $15.00
Fundamentals
Cross Country Healthcare, Inc. provides talent management services for healthcare clients in the United States. The company operates in two segments: Nurse and Allied Staffing, and Physician Staffing. The Nurse and Allied Staffing segment provides tr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$323.92M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.38%
Volume
Today's trading volume
216,740
Recent News
Zacks.com featured highlights include Cable One, Phillips 66, Archer Daniels Midland, CVR Energy and Cross Country Healthcare
Cable One stands out among broker-backed picks as rising earnings estimates and strong growth forecasts draw attention amid volatile, oil-driven markets.
5 Broker-Liked Stocks Worth Tracking Amid the Middle East Conflict
Broker-favored stocks like PSX, CABO and others stand out as Iran-Israel war jolts oil and markets.
How The Cross Country Healthcare (CCRN) Story Is Shifting With Margin Goals And Travel Nurse Demand
Recent research keeps Cross Country Healthcare’s fair value estimate steady at US$11.67, while price targets have been set in a US$10 to US$14 range. This provides a clear reference band for how analysts are framing potential outcomes. Those targets sit alongside mixed commentary, with bullish views tied to travel nurse demand and margin goals, and more cautious voices pointing to execution risks and the possibility that some good news is already priced in. Read on to see how to track these...
How The Narrative Is Shifting For Cross Country Healthcare (CCRN) After Mixed Margin Expectations
The updated analyst fair value estimate for Cross Country Healthcare now sits at US$11.67, compared with the prior US$9.93. This keeps the current target in the low double digits. This shift lines up with research that highlights a mix of optimism and caution, including raised targets clustered between roughly US$10 and the low to mid teens, as analysts weigh execution in higher margin areas against lingering risks. As you read on, you will see how these moving targets shape the evolving...
Does Cross Country Healthcare (CCRN) Have Strong Fundamentals?
Long Cast Advisers, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Portfolio’s cumulative net return increased by 1%, but the cumulative portfolio for the year remained flat. Since its inception in November 2015, the portfolio has delivered a cumulative return […]